INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 201 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is 1.09 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $6,228,000 | +148.7% | 50,260 | +33.2% | 1.44% | +124.5% |
| Q3 2019 | $2,504,000 | -17.3% | 37,734 | -0.9% | 0.64% | -10.9% |
| Q2 2019 | $3,029,000 | -28.7% | 38,073 | +0.3% | 0.72% | -32.6% |
| Q1 2019 | $4,247,000 | +110.5% | 37,970 | +89.6% | 1.06% | +74.9% |
| Q4 2018 | $2,018,000 | -47.5% | 20,025 | -34.1% | 0.61% | -33.2% |
| Q3 2018 | $3,841,000 | +1019.8% | 30,395 | +1281.6% | 0.91% | +785.4% |
| Q4 2014 | $343,000 | -34.2% | 2,200 | 0.0% | 0.10% | -35.6% |
| Q3 2014 | $521,000 | 0.0% | 2,200 | 0.0% | 0.16% | -2.4% |
| Q2 2014 | $521,000 | -28.2% | 2,200 | 0.0% | 0.16% | -32.0% |
| Q1 2014 | $726,000 | +165.9% | 2,200 | -45.0% | 0.24% | +159.1% |
| Q4 2013 | $273,000 | – | 4,000 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |